Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
The SURPASS and SURMOUNT trial programs Tirzepatide was evaluated in over 10,000 participants across the SURPASS (type 2 diabetes) and SURMOUNT (obesity) trial programs
Your GP can tell you
Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes
Although weight loss injectables are not directly associated with DVT, its use in patients with multiple risk factors for clotting disorders, such as obesity or prolonged immobility, may increase that risk unnecessarily
US$ 27.79
US$ 20.62
US$ 22.67
00182-7/asset/aed83eb5-c537-40e6-bd67-6ea417eca1be/main.assets/gr3_lrg.jpg)
US$ 22.73
